GILD — Gilead Sciences Balance Sheet
0.000.00%
HealthcareConservativeLarge CapSuper Stock
- $105.44bn
- $124.98bn
- $27.31bn
- 97
- 51
- 93
- 93
Annual balance sheet for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 25,510 | 30,089 | 24,352 | 7,408 | 6,520 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,851 | 3,327 | 3,582 | 4,892 | 4,493 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 31,823 | 35,836 | 30,296 | 15,996 | 14,772 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,295 | 4,006 | 5,170 | 5,613 | 5,663 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 70,283 | 63,675 | 61,627 | 68,407 | 67,952 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11,635 | 10,605 | 9,759 | 11,397 | 11,610 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 49,841 | 42,288 | 39,102 | 50,205 | 46,883 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 20,442 | 21,387 | 22,525 | 18,202 | 21,069 |
Total Liabilities & Shareholders' Equity | 70,283 | 63,675 | 61,627 | 68,407 | 67,952 |
Total Common Shares Outstanding |